A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment

References

• Dennis ML, Scott CK, Funk R, Foss MA. The duration and correlates of addiction and treatment careers. J Subst Abuse Treat 2005;28:S51–S62
   PubMed Web of Science ®Google Scholar
• Anglin MD, Hser YI, Grella CE. Drug addiction and treatment careers among clients in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav 1997;11:308–323
   Web of Science ®Google Scholar
• McPeake JD, Kennedy BP, Gordon SM. Altered states of consciousness therapy: a missing component in alcohol and drug rehabilitation treatment. J Subst Abuse Treat 1991;8:75–82
   PubMedGoogle Scholar
• Bogenschutz MP, Pommy JM. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses. Drug Test Anal 2012;4:543–555
   PubMed Web of Science ®Google Scholar
• Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study. Arch Gen Psychiatry 1973;28:808–814
   PubMed Web of Science ®Google Scholar
• Krebs TS, Johansen PO. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 2012;26:994–1002
   PubMed Web of Science ®Google Scholar
• Fábregas JM, González D, Fondevila S, Cutchet M, Fernández X, Barbosa PCR, Alcázar-Córcoles MT, et al. Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend 2010;111:257–261
   PubMed Web of Science ®Google Scholar
• Grob CS, McKenna DJ, Callaway JC, Brito GS, Neves ES, Oberlaender G, Saide OL, et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis 1996;184:86–94
   PubMed Web of Science ®Google Scholar
• Halpern JH, Sherwood AR, Passie T, Blackwell KC, Ruttenber AJ. Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med Sci Monit 2008;14:SR15–SR22
   PubMed Web of Science ®Google Scholar
• Krupitsky EM, Grinenko AY. Ketamine-assisted psychotherapy (KPT) of alcoholism. Alcologia 1996;8:161–176
   Google Scholar
• Krupitsky E, Burakov A, Romanova T, Dunaevsky I, Strassman R, Grinenko A. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat 2002;23:273–283
   PubMed Web of Science ®Google Scholar
• Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs 2007;39:13–19
   PubMed Web of Science ®Google Scholar
• Soskin RA. Personality and attitude change after two alcoholism treatment programs. Comparative contributions of lysergide and Human Relations Training. Q J Stud Alcohol 1970;31:920–931
   PubMedGoogle Scholar
• Pahnke WN, Kurland AA, Unger S, Savage C, Grof S. The experimental use of psychedelic (LSD) psychotherapy. JAMA 1970;212:1856–1863
   PubMed Web of Science ®Google Scholar
• Johnson FG. LSD in the treatment of alcoholism. Am J Psychiatry 1969;126:481–487
   PubMed Web of Science ®Google Scholar
• Blum K, Futterman SL, Pascarosa P. Peyote, a potential ethnopharmacologic agent for alcoholism and other drug dependencies: possible biochemical rationale. Clin Toxicol 1977;11:459–472
   PubMed Web of Science ®Google Scholar
• Strassman RJ. Hallucinogenic drugs in psychiatric research and treatment. J Nerv Ment Dis 1995;183:127–138
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Nutt DJ. User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study. J Subst Use 2010;15:283–300
   Web of Science ®Google Scholar
• Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol 2008;22:603–620
   PubMed Web of Science ®Google Scholar
• Frecska E, Luna LE. The adverse effects of hallucinogens from intramural perspective. Neuropsychopharmacol Hung 2006;8:189–200
   PubMedGoogle Scholar
• Carhart-Harris RL, Williams TM, Sessa B, Tyacke RJ, Rich AS, Feilding A, Nutt DJ. The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability. J Psychopharmacol 2011;25:1562–1567
   PubMedGoogle Scholar
• Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006;67:1735–1740
   PubMed Web of Science ®Google Scholar
• Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 2008;14:295–314
   PubMed Web of Science ®Google Scholar
• Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol 2002;7:357–364
   PubMed Web of Science ®Google Scholar
• Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 2011;25:1434–1452
   PubMed Web of Science ®Google Scholar
• Alper KR, Lotsof HS, Frenken GMN, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. Am J Addict 1999;8:234–242
   PubMed Web of Science ®Google Scholar
• Grinspoon L, Doblin R. Psychedelics as catalysts of insight-oriented psychotherapy. Soc Res 2001;68:676–695
   Google Scholar
• Dyck E. ‘Hitting highs at rock bottom’: LSD treatment for alcoholism, 1950-1970. Soc Hist Med 2006;19:313–329
   Web of Science ®Google Scholar
• Strassman R. DMT: the spirit molecule: a doctor’s revolutionary research into the biology of near-death and mystical experience. Rochester (VT): Park Street Press; 2001
   Google Scholar
• Moreno FA. Progress report: the psilocybin/obsessive-compulsive disorder (OCD) study obtains final FDA approval. MAPS Bull 2001;11:1–2
   Google Scholar
• MačiIulaitis R, Kontrimavičiute V, Bressolle FMM, Briedis V. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Hum Exp Toxicol 2008;27:181–194
   PubMedGoogle Scholar
• Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 2010;11:642–651
   PubMed Web of Science ®Google Scholar
• Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 2005;38:301–311
   PubMedGoogle Scholar
• Kumar S. Clinical study protocol: psilocybin-assisted psychotherapy in the management of anxiety associated with stage IV melanoma. MAPS 2007; final version, IND[79,321]
   Google Scholar
• Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstad AL, Greer GR. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011;68:71–78
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 2011;25:439–452
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 1998;9:3897–3902
   PubMed Web of Science ®Google Scholar
• Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry 2012;72:898–906
   PubMed Web of Science ®Google Scholar
• Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 2011;61:364–381
   PubMed Web of Science ®Google Scholar
• Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett 2011;493:76–79
   PubMed Web of Science ®Google Scholar
• Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology 2012;223:1–15
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, Hobden P, et al. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry 2012;200:238–244
   PubMedGoogle Scholar
• Foa EB, Keane TM, Friedman MJ, et al. Effective treatments for PTSD: practice guidelines from the International Society for Traumatic Stress Studies. 2nd ed. New York (NY): Guilford Press; 2009
   Google Scholar
• Cook CCH. Addiction and spirituality. Addiction 2004;99:539–551
   PubMed Web of Science ®Google Scholar
• Pahnke WN. Psychedelic drugs and mystical experience. Int Psychiatry Clin 1969;5:149–162
   PubMedGoogle Scholar
• Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 2011;218:649–665
   PubMed Web of Science ®Google Scholar
• Matzger H, Kaskutas LA, Weisner C. Reasons for drinking less and their relationship to sustained remission from problem drinking. Addiction 2005;100:1637–1646
   PubMed Web of Science ®Google Scholar
• Kemp R. Relating to the other: truth and untruth in addiction. Eur J Psychother Counsell Health 2009;11:355–368
   Google Scholar
• Bliss DL. Severity of alcohol dependence: impact on spirituality in early treatment process. Alcohol Treat Q 2009;27:66–81
   Google Scholar
• Kelly JF, Hoeppner B, Stout RL, Pagano M. Determining the relative importance of the mechanisms of behavior change within alcoholics anonymous: a multiple mediator analysis. Addiction 2012;107:289–299
   PubMed Web of Science ®Google Scholar
• Zemore SE. A role for spiritual change in the benefits of 12-step involvement. Alcohol Clin Exp Res 2007;31:76s–79s
   PubMed Web of Science ®Google Scholar
• Carter TM. The effects of spiritual practices on recovery from substance abuse. J Psychiatr Ment Health Nurs 1998;5:409–413
   PubMedGoogle Scholar
• Dawson DA, Goldstein RB, Ruan WJ, Grant BF. Correlates of recovery from alcohol dependence: a prospective study over a 3-year follow-up interval. Alcohol Clin Exp Res 2012;36:1268–1277
   PubMed Web of Science ®Google Scholar
• Galanter M, Dermatis H, Bunt G, Williams C, Trujillo M, Steinke P. Assessment of spirituality and its relevance to addiction treatment. J Subst Abuse Treat 2007;33:257–264
   PubMed Web of Science ®Google Scholar
• Green LL, Fullilove MT, Fullilove RE. Stories of spiritual awakening: the nature of spirituality in recovery. J Subst Abuse Treat 1998;15:325–331
   PubMed Web of Science ®Google Scholar
• Kelly JF, Stout RL, Magill M, Tonigan JS, Pagano ME. Spirituality in recovery: a lagged mediational analysis of alcoholics anonymous’ principal theoretical mechanism of behavior change. Alcohol Clin Exp Res 2011;35:454–463
   PubMed Web of Science ®Google Scholar
• Pardini DA, Plante TG, Sherman A, Stump JE. Religious faith and spirituality in substance abuse recovery: determining the mental health benefits. J Subst Abuse Treat 2000;19:347–354
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 2006;187:268–283
   PubMed Web of Science ®Google Scholar
• Vaitl D, Gruzelier J, Jamieson GA, Lehmann D, Ott U, Sammer G, Strehl U, et al. Psychobiology of altered states of consciousness. Psychol Bull 2005;131:98–127
   PubMed Web of Science ®Google Scholar
• Brewerton TD, Eyerman JE, Cappetta P, Mithoefer MC. Long-term abstinence following Holotropic Breathwork as adjunctive treatment of substance use disorders and related psychiatric comorbidity. Int J Ment Health Addict 2012;10:453–459
   Google Scholar
• Holmes SW, Morris R, Clance PR, Putney RT. Holotropic Breathwork: an experiential approach to psychotherapy. Psychotherapy 1996;33:114–120
   Google Scholar
• Rhinewine JP, Williams OJ. Holotropic Breathwork: the potential role of a prolonged, voluntary hyperventilation procedure as an adjunct to psychotherapy. J Altern Complement Med 2007;13:771–776
   PubMed Web of Science ®Google Scholar
• Lempert T, Bauer M, Schmidt D. Syncope: a videometric analysis of 56 episodes of transient cerebral hypoxia. Ann Neurol 1994;36:233–237
   PubMedGoogle Scholar
• Morgan CJA, Curran HV. Ketamine use: a review. Addiction 2012;107:27–38
   PubMed Web of Science ®Google Scholar
• Johanson CE, Balster RL. A summary of the results of a drug self-administation study using substitution procedures in rhesus monkeys. Bull Narc 1978;30:43–54
   PubMedGoogle Scholar
• Fantegrossi WE, Woods JH, Winger G. Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol 2004;15:149–157
   PubMed Web of Science ®Google Scholar
• Poling A, Bryceland J. Voluntary drug self-administration by nonhumans: a review. J Psychedelic Drugs 1979;11:185–190
   PubMed Web of Science ®Google Scholar
• Morgan CJA, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2010;105:121–133
   PubMed Web of Science ®Google Scholar
• Wai MSM, Chan WM, Zhang AQ, Wu Y, Yew DT. Long-term ketamine and ketamine plus alcohol treatments produced damages in liver and kidney. Hum Exp Toxicol 2012;31:877–886
   PubMed Web of Science ®Google Scholar
• Gable RS. The toxicity of recreational drugs. Am Scientist 2006;94:206
   Web of Science ®Google Scholar
• CDC. Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR 2011;60:1–6
   Google Scholar
• Substance Abuse and Mental Health Services, US Department of Health and Human Services. Results from the 2010 national survey on drug use and health: summary of national findings. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2011
   Google Scholar
• Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011;68:1238–1246
   PubMed Web of Science ®Google Scholar
• Hjorthøj CR, Hjorthøj AR, Nordentoft M. Validity of timeline follow-back for self-reported use of cannabis and other illicit substances – systematic review and meta-analysis. Addict Behav 2012;37:225–233
   PubMed Web of Science ®Google Scholar
• Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One 2010;5:e12412g
   Google Scholar